Drug-induced Sweet's syndrome secondary to hepatitis C antiviral therapy

Liana Gheorghe; Bogdan Cotruta; Viorel Trifu; Cristina Cotruta; Gabriel Becheanu; Cristian Gheorghe

doi:10.1111/j.1365-4632.2008.03724.x

Drug-induced Sweet's syndrome secondary to hepatitis C antiviral therapy

Int J Dermatol. 2008 Sep;47(9):957-9. doi: 10.1111/j.1365-4632.2008.03724.x.

Authors

Liana Gheorghe¹, Bogdan Cotruta, Viorel Trifu, Cristina Cotruta, Gabriel Becheanu, Cristian Gheorghe

Affiliation

¹ Department of Gastroenterology and Hepatology, Fundeni Clinical Institute, Bucharest, Romania. [email protected]

PMID: 18937663
DOI: 10.1111/j.1365-4632.2008.03724.x

Abstract

Pegylated interferon-alpha in combination with ribavirin currently represents the therapeutic standard for the hepatitis C virus infection. Interferon based therapy may be responsible for many cutaneous side effects. We report a case of drug-induced Sweet's syndrome secondary to hepatitis C antiviral therapy. To our knowledge, this is the first reported case of Sweet's syndrome in association with pegylated interferon-alpha therapy.

Publication types

Case Reports

MeSH terms

Administration, Oral
Biopsy, Needle
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Hepatitis C, Chronic / diagnosis
Hepatitis C, Chronic / drug therapy*
Humans
Immunohistochemistry
Injections, Subcutaneous
Interferon alpha-2
Interferon-alpha / adverse effects*
Interferon-alpha / therapeutic use
Middle Aged
Prednisone / administration & dosage
Recombinant Proteins
Ribavirin / adverse effects*
Ribavirin / therapeutic use
Risk Assessment
Sweet Syndrome / chemically induced*
Sweet Syndrome / drug therapy
Sweet Syndrome / pathology
Treatment Outcome

Substances

Interferon alpha-2
Interferon-alpha
Recombinant Proteins
Ribavirin
Prednisone